The 36-month beta value for RNAZ is also noteworthy at 0.64. There are mixed opinions on the stock, with 1 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for RNAZ is 17.23M, and at present, short sellers hold a 8.03% of that float. The average trading volume of RNAZ on October 23, 2024 was 2.18M shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
RNAZ) stock’s latest price update
The stock price of TransCode Therapeutics Inc (NASDAQ: RNAZ) has jumped by 16.41 compared to previous close of 0.61. Despite this, the company has seen a gain of 4.56% in its stock price over the last five trading days. globenewswire.com reported 2024-09-17 that Two patients dosed; several additional patients screened for enrollment Trial to evaluate safety and tolerability of TTX-MC138 in patients with metastatic cancer TTX-MC138 is an antisense oligonucleotide conjugated to TransCode’s proprietary TTX delivery system designed to inhibit microRNA-10b, a known driver of metastasis in multiple cancers Phase 1 clinical trial follows evidence of delivery and pharmacodynamic activity in prior first-in-human Phase 0 clinical trial with radiolabeled TTX-MC138 BOSTON, Sept. 17, 2024 (GLOBE NEWSWIRE) — TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced dosing of the first two patients in its Phase 1 clinical trial with its lead candidate, TTX-MC138.
RNAZ’s Market Performance
RNAZ’s stock has risen by 4.56% in the past week, with a monthly rise of 70.33% and a quarterly rise of 135.37%. The volatility ratio for the week is 11.71% while the volatility levels for the last 30 days are 24.73% for TransCode Therapeutics Inc The simple moving average for the last 20 days is 15.75% for RNAZ’s stock, with a simple moving average of -11.79% for the last 200 days.
RNAZ Trading at 68.53% from the 50-Day Moving Average
After a stumble in the market that brought RNAZ to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -96.57% of loss for the given period.
Volatility was left at 24.73%, however, over the last 30 days, the volatility rate increased by 11.71%, as shares surge +9.93% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +188.78% upper at present.
During the last 5 trading sessions, RNAZ rose by +4.99%, which changed the moving average for the period of 200-days by -87.64% in comparison to the 20-day moving average, which settled at $0.6139. In addition, TransCode Therapeutics Inc saw -89.23% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for RNAZ
Current profitability levels for the company are sitting at:
- -23.67 for the present operating margin
- 0.25 for the gross margin
The net margin for TransCode Therapeutics Inc stands at -23.77. The total capital return value is set at -13.48. Equity return is now at value -1048.70, with -334.48 for asset returns.
Based on TransCode Therapeutics Inc (RNAZ), the company’s capital structure generated 0.15 points at debt to capital in total, while cash flow to debt ratio is standing at -67.97. The debt to equity ratio resting at 0.17. The interest coverage ratio of the stock is -351.8.
Currently, EBITDA for the company is -18.9 million with net debt to EBITDA at 0.18. When we switch over and look at the enterprise to sales, we see a ratio of 12.05. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.25.
Conclusion
In summary, TransCode Therapeutics Inc (RNAZ) has had a mixed performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
